Current stock page

Stock Analysis

Spyre Therapeutics, Inc. (SYRE) Stock Analysis

Spyre Therapeutics, Inc. (SYRE) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.

SYRE Stock Analysis Summary

Spyre Therapeutics, Inc. (SYRE) currently has an AIQ Score of 64/100, indicating a neutral setup. Momentum is the strongest factor at 81/100. Value is the weakest current factor at 44/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data

SYRE at a Glance

Crawlable current metrics from the latest market-close stock snapshot.

MetricCurrent
Price$104.00
AIQ Score64/100
Overall ViewNeutral
Technical Analysis ConsensusStrong Buy
Market Cap$9.19B
P/E Ratio (TTM)-37.96
Forward P/E—
EPS (Q3 FY2026)-$0.94
Revenue (Q3 FY2026)$0
Dividend Yield (TTM)0.00%
Beta1.69
Volume746.24K
52-week range$22.13-$110.64
RSI 1459.4
50-Day SMA$91.48
200-Day SMA$76.67
Analyst Price Target$122.83
Next EarningsFeb 18, 2027
As of Nov 13, 2026 · Market close

SYRESpyre Therapeutics, Inc.

Healthcare / Biotechnology

Low Priority

Above Peers

NeutralEdge 7/10
$104.00+$1.09 (+1.06%)

Latest quote

  • Momentum
    81
  • Value
    44
  • Quality
    61
  • Risk resilience
    53
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

SYRE Stock Analysis Summary

Spyre Therapeutics, Inc. (SYRE) currently has an AIQ Score of 64/100, indicating a neutral setup. Momentum is the strongest factor at 81/100. Value is the weakest current factor at 44/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data
AIQ Composite Posture: Neutral

In a neutral regime, SYRE has AIQ Score of 64/100 with Momentum base of 81/100 and fading Value at 44/100. Wait for component alignment before adding exposure.

Signal Conflict Detected

Momentum (81/100) leads while Value (44/100) lags. This cross-factor spread creates entry timing uncertainty.

Healthcare · 1.06% stock move · SYRE classified in Biotechnology.

Current Evidence

NeutralSYRE is in a neutral AIQ regime; Momentum is the strongest visible factor at 81/100.
Core coverage reflects visible evidence only

AlgovestIQ Evidence Summary

Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.

Is SYRE Bullish or Bearish Right Now?

SYRE currently has a neutral overall setup. Momentum is the strongest factor at 81/100, while Value is weakest at 44/100. The current evidence suggests a mixed rather than strongly bullish or bearish setup.

Bull Case
  • - Momentum is constructive at 81/100.
  • - Price is +13.68% above its 50-day SMA.
  • - Analyst target implies +18.11% upside from the latest quote.
  • - Technical consensus has more buy votes than sell votes (34 vs 3).
Bear Case
  • - Value is the current constraint at 44/100.

Current Consensus

SYRE's Technical Analysis Consensus is currently Strong Buy, with 34 buy, 9 neutral, and 3 sell votes. SYRE's 14-day RSI is 59.4, which places the stock in a constructive momentum range. SYRE's beta is 1.69, indicating greater market sensitivity than the broad market.

Signal Confidence
High agreement

What Changed in SYRE?

The largest recent change in SYRE is Momentum moving up by 4.0 points over the available 7-day comparison window. Momentum remains the strongest visible factor.

AIQ Score
+2.0
Momentum
+4.0
Quality
+1.0
Risk
+0.0

What Would Change the SYRE Outlook?

The current neutral outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.

Bullish confirmation

AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.

Bearish deterioration

AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.

SYRE Decision Framework

Public evidence layers, setup checks, and risk context for Spyre Therapeutics, Inc..

Spyre Therapeutics, Inc. (SYRE) Stock Analysis

Spyre Therapeutics, Inc. has an AIQ Score of 64/100 in a Neutral regime. Momentum is strongest at 81/100. Beta is 1.69, above market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.

Evidence LayerPublic Evidence
Regime ContextSYRE is in a Neutral AIQ regime with score 64/100.
Signal ConflictThe primary conflict is that momentum leads at 81/100 while value lags at 44/100.
Factor EvidenceMomentum 81/100 · Value 44/100 · Quality 61/100 · Risk 53/100
PersistenceCurrent snapshot evidence is shown; historical persistence remains in AIQ Pro.

Current Setup Checklist

Factor strengthPass

Momentum is the strongest factor at 81/100.

TimingPass

Momentum is 81/100 and RSI (14) is 59.4.

Regime fitWait

SYRE is in a Neutral regime at 64/100.

Risk controlWait

Risk factor is 53/100 with beta 1.69 and annual volatility 66.66%.

ConflictWait

Current conflict: momentum leads at 81/100 while value lags at 44/100.

AIQ Score
64/100
Price
$104.00
Beta
1.69
RSI (14)
59.4

SYRE Research Cluster

Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.

SYRE Fundamentals

SYRE valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.

Revenue
$0
Net income
-$96.12M
Free cash flow
-$77.5M
View full SYRE fundamental analysis

SYRE Technical Analysis

SYRE technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.

Technical Analysis Consensus
Strong Buy
RSI 14
59.4
Price vs SMA-50
+13.68%
View full SYRE technical analysis

SYRE Stock Catalysts

Track SYRE earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.

Next earnings
Feb 18, 2027
Analyst target
$122.83
News items
0
View SYRE earnings and stock catalysts

SYRE Dividend Analysis

SYRE dividend yield, annual dividend, payout ratio, payment history, and income reliability context.

Dividend yield
0.00%
Annual dividend
—
Payout ratio
—
View SYRE dividend history and analysis

SYRE Financial Data

SYRE revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.

Quarter revenue
$0
EPS
-$0.94
Periods
8
View SYRE financials

SYRE Risk Analysis

SYRE volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.

Beta
1.69
Risk score
53/100
1Y volatility
66.66%
View SYRE risk analysis

SYRE Stock News

SYRE stock news, market tone, recent headlines, and catalyst context.

News items
0
Updated
—
Sentiment
—
Read SYRE stock news

SYRE vs Biotechnology Peers

Current peer cohort: SYRE · TARS · TGTX · TNGX · TRVI. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.

PeerAIQValueMomentumRiskSharpe1Y VolatilityCompare
SYRE
Current stock
64/10044/10081/10053/1002.5766.66%Current
TARS
Tarsus Pharmaceuticals, Inc.
65/10075/10076/10059/1000.3645.02%SYRE vs TARS
TGTX
TG Therapeutics, Inc.
76/10065/10093/10063/1001.7446.06%SYRE vs TGTX
TNGX
Tango Therapeutics, Inc.
61/100—60/10038/1001.61101.07%SYRE vs TNGX
TRVI
Trevi Therapeutics, Inc.
63/100—52/10051/1000.5259.27%SYRE vs TRVI
Pairwise Compare links: TARS · TGTX · TNGX · TRVISYRE vs TARSSYRE vs TGTXSYRE vs TNGXSYRE vs TRVICompare cohort

Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.

About the AIQ Score

Methodology for the current stock evidence.

As of Nov 13, 2026 · Market close

The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.

View AIQ methodology

Factor Diagnostics

A compact bridge from the AIQ score to the evidence tabs.

Calculator
Calculate a SYRE stock return scenario

Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.

Calculate stock return

Also for SYRE: historical return with reinvested dividends and stock average calculator for several buys.

AIQ Component Profile

Compare the five component scores on one consistent 0–100 scale.

Catalyst preview

Review earnings timing, revisions, news pressure, and prior event reactions in one place.

Open catalysts
Quarterly evidence

8 recent quarterly periods are available for review.

Checked Nov 16, 2026

AIQ Pro

Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.

Fundamentals Verdict

Current snapshot fields are separate from reported-quarter statement tables.

Current TTM P/E
-37.96
As of Nov 13, 2026
Revenue growth
—
Gross margin
50.00%
Current debt / equity
0
Latest quarterly evidence

Latest period Sep 30, 2026.

Review fundamentals
Quarter revenue
$0
Quarter net income
-$96.12M
Quarter free cash flow
-$77.5M

Market Confirmation

Technicals are summarized first, with the indicator library behind it.

Trend
Bullish
Momentum
Bullish
RSI 14
59.4
MACD
4.23

Risk Alignment

Higher resilience is stronger; exposure metrics stay separate.

Resilience
53/100
Beta
1.69
Annual volatility
66.66%
Max drawdown
-27.81%

SYRE Stock FAQ

What is SYRE stock price today?

Spyre Therapeutics, Inc.'s current stock price is $104.00. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.

Is SYRE bullish or bearish right now?

SYRE's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.

What is SYRE's market cap?

SYRE's market cap is $9.19B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.

What is SYRE's current P/E ratio?

SYRE's current P/E ratio is -37.96 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.

What is SYRE's RSI?

SYRE's 14-day RSI is 59.4 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.

Is SYRE above its 50-day and 200-day moving averages?

SYRE is 13.68% from its 50-day SMA and 35.65% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.

When is SYRE's next earnings date?

SYRE's next earnings date is currently listed as Feb 18, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.

Does SYRE pay a dividend?

SYRE's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.